Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with platinum-containing chemotherapy, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small-cell lung carcinoma at high risk of recurrence in adults'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price is £2,630 per 100‑mg vial (excluding VAT; BNF online accessed August 2024).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.